The online version of this article (doi:10.1186/1476-4598-11-88) contains supplementary material, which is available to authorized users.
TF applied a patent on siRNAs used in this study. Other authors declare that they have no competing interests.
TF designed the study. TF and ET carried out in vitro and in vivo experiments and analyzed data. TF, YK, TH, MY, KShim, NS and KShir obtained, examined and analyzed surgical materials. TF wrote the manuscript. All authors had final approval of the submitted and published versions.
Pancreatic cancer is characterized by constitutive activation of mitogen-activated protein kinase (MAPK). Activation of MAPK is associated with the upregulation of genes implicated in the proliferation and survival of pancreatic cancer cells. We hypothesized that knockdown of these MAPK-associated molecules could produce notable anticancer phenotypes.
A RNA interference-mediated knockdown screening of 78 MAPK-associated molecules previously identified was performed to find molecules specifically associated with proliferation of pancreatic cancer cells in vitro. Expression of an identified molecule in pancreatic cancer tissues was examined by immunohistochemistry. In vivo tumorigenicity of cancer cells with stable knockdown of the molecule was assayed by using xenograft models. Flow cytometry and live cell imaging were employed to assess an association of the molecule with cell cycle.
The knockdown screening revealed that knockdown of SON, the gene encoding SON, which is a large serine/arginine-rich protein involved in RNA processing, substantially suppressed pancreatic cancer cell proliferation and survival in vitro and tumorigenicity in vivo. SON expression was higher in ductal adenocarcinomas than in cells of normal ducts and precursor lesions in pancreatic cancer tissues. Knockdown of SON induced G2/M arrest and apoptosis in cultured cancer cells. The suppressive effect of SON knockdown on proliferation was less pronounced in cultured normal duct epithelial cells. SON formed nuclear speckles in the interphase of the cell cycle and dispersed in the cytoplasm during mitosis. Live cell imaging showed that SON diffusely dispersed in the early mitotic phase, accumulated in some foci in the cytoplasm in the late mitotic phase, and gradually reassembled into speckles after mitosis.
These results indicate that SON plays a critical role in the proliferation, survival, and tumorigenicity of pancreatic cancer cells, suggesting that SON is a novel therapeutic molecular target for pancreatic cancer.
Additional file 1: Table S1. Short interfering RNAs used in a systematic knockdown screening of MAPK-assoicated genes in pancreatic cancer. (PDF 37 KB)12943_2012_1079_MOESM1_ESM.pdf
Authors’ original file for figure 112943_2012_1079_MOESM2_ESM.tiff
Authors’ original file for figure 212943_2012_1079_MOESM3_ESM.tiff
Authors’ original file for figure 312943_2012_1079_MOESM4_ESM.tiff
Authors’ original file for figure 412943_2012_1079_MOESM5_ESM.tiff
Authors’ original file for figure 512943_2012_1079_MOESM6_ESM.tiff
Cancer statistics in Japan. Edited by: Kato H, Sobue T, Katanoda K, Saito Y, Tsukuma H, Sakura N, Kitai A. 2008, National Cancer Center, Tokyo.
Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007, 8 (9): 773-783. 10.1016/S1470-2045(07)70245-0 CrossRefPubMed
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348 (11): 994-1004. 10.1056/NEJMoa022457 CrossRefPubMed
Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003, 163 (4): 1255-1260. 10.1016/S0002-9440(10)63485-2 PubMedCentralCrossRefPubMed
Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005, 65 (7): 2899-2905. 10.1158/0008-5472.CAN-04-3981 CrossRefPubMed
Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep. 2001, 8 (1): 89-92. PubMed
Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N: Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. Lab Invest. 2004, 84 (10): 1339-1351. 10.1038/labinvest.3700160 CrossRefPubMed
Leser GP, Fakan S, Martin TE: Ultrastructural distribution of ribonucleoprotein complexes during mitosis. snRNP antigens are contained in mitotic granule clusters. Eur J Cell Biol. 1989, 50 (2): 376-389. PubMed
Bubulya PA, Prasanth KV, Deerinck TJ, Gerlich D, Beaudouin J, Ellisman MH, Ellenberg J, Spector DL: Hypophosphorylated SR splicing factors transiently localize around active nucleolar organizing regions in telophase daughter nuclei. J Cell Biol. 2004, 167 (1): 51-63. 10.1083/jcb.200404120 PubMedCentralCrossRefPubMed
- Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II